Literature DB >> 35263865

Comparison between Oblique Lumbar Interbody Fusion (OLIF) and Minimally Invasive Transforaminal Lumbar Interbody Fusion (MISTLIF) for Lumbar Spondylolisthesis.

Vemula V R Chandra1, Bodapati C M Prasad1, Tammireddy G Hanu1, Pavan G Kale1.   

Abstract

Background: Lumbar interbody fusion has gained popularity for the treatment of spondylolisthesis in recent years. Both procedures have their own advantages and disadvantages. Objective: The aim of this study was to compare the clinical and radiological outcomes of MIS TLIF and OLIF in terms of visual analog score, Oswestry Disability Index, Intraoperative blood loss, and various other parameters. Material and
Methods: This is a retrospective matched-pair comparative analysis between two groups who underwent Single level either OLIF or MISTLIF for spondylolisthesis operated from January 2017 to January 2020 at a Single institute by a Single surgeon.
Results: Statistically there is no difference in various preoperative parameters between the two groups. The intraoperative blood loss is 112.5 mL in OLIF, and 144.6 mL is MISTLIF. The duration of surgery in OLIF is 4.41 h and 3.16 h in MISTLIF. The mean duration of the requirement of postoperative analgesia is 3 months after OLIF and 5 months after MISTLIF. The time taken for returning to regular activities is less in OLIF than MISTLIF. Conclusions: Although both OLIF and MISTLIF have almost equivalent outcomes, OLIF is better than MISTLIF in having lesser intraoperative blood loss and achieving better lordotic correction.

Entities:  

Keywords:  MISTLIF; ODI; OLIF; VAS

Mesh:

Year:  2022        PMID: 35263865     DOI: 10.4103/0028-3886.338732

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  1 in total

1.  Anatomical characteristics affecting the surgical approach of oblique lateral lumbar interbody fusion: an MR-based observational study.

Authors:  Meng-Long Han; Wei-Hong He; Zhong-Yun He; Xue-Liang Yan; Xiang-Jun Fang
Journal:  J Orthop Surg Res       Date:  2022-09-24       Impact factor: 2.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.